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http://dx.doi.org/10.1053/j.gastro.2017.02.010BACKGROUND & AIMS: Endoscopists do not routinely follow
guidelines to survey individuals with low-risk adenomas (LRAs;
1–2 small tubular adenomas, < 1 cm) every 5–10 years for
colorectal cancer; many recommend shorter surveillance in-
tervals for these individuals. We aimed to identify the reasons
that endoscopists recommend shorter surveillance intervals for
some individuals with LRAs and determine whether timing
affects outcomes at follow-up examinations. METHODS: We
collected data from 1560 individuals (45–75 years old) who
participated in a prospective chemoprevention trial (of vitamin
D and calcium) from 2004 through 2008. Participants in the
trial had at least 1 adenoma, detected at their index colonos-
copy, and were recommended to receive follow-up colonoscopy
examinations at 3 or 5 years after adenoma identification, as
recommended by the endoscopist. For this analysis we
collected data from only participants with LRAs. These data
included characteristics of participants and endoscopists and
findings from index and follow-up colonoscopies. Primary
endpoints were frequency of recommending shorter (3-year) vs
longer (5-year) surveillance intervals, factors associated with
these recommendations, and effect on outcome, determined at
the follow-up colonoscopy. RESULTS: A 3-year surveillance
interval was recommended for 594 of the subjects (38.1%).
Factors most significantly associated with recommendation of
3-year vs a 5-year surveillance interval included African
American race (relative risk [RR] to white, 1.41; 95% confi-
dence interval [CI], 1.14–1.75), Asian/Pacific Islander ethnicity
(RR to white, 1.7; 95% CI, 1.22–2.43), detection of 2 adenomas
at the index examination (RR vs 1 adenoma, 1.47; 95% CI, 1.27–
1.71), more than 3 serrated polyps at the index examination
(RR¼2.16, 95% CI, 1.59–2.93), or index examination with fairor poor quality bowel preparation (RR vs excellent quality,
2.16; 95% CI, 1.66–2.83). Other factors that had a significant
association with recommendation for a 3-year surveillance in-
terval included family history of colorectal cancer and detection
of 1–2 serrated polyps at the index examination. In compari-
sons of outcomes, we found no significant differences between
the 3-year vs 5-year recommendation groups in proportions of
subjects found to have 1 or more adenomas (38.8% vs 41.7%
respectively; P ¼ .27), advanced adenomas (7.7% vs 8.2%;
P ¼ .73) or clinically significant serrated polyps (10.0% vs
10.3%; P ¼ .82) at the follow-up colonoscopy. CONCLUSIONS:
Possibly influenced by patients’ family history, race, quality of
bowel preparation, or number or size of polyps, endoscopists
frequently recommend 3-year surveillance intervals instead of
guideline-recommended intervals of 5 years or longer for in-
dividuals with LRAs. However, at the follow-up colonoscopy,
similar proportions of participants have 1 or more adenomas,
advanced adenomas, or serrated polyps. These findings support
the current guideline recommendations of performing follow-up
examinations of individuals with LRAs at least 5 years after the
index colonoscopy.Keywords: Colon Cancer; Detection; Tumor Development;
Progression.
EDITOR’S NOTES
BACKGROUND AND CONTEXT
Endoscopists often recommend intervals for follow-up
colonoscopy that are shorter than those in published
guidelines for individuals with 1-2 small tubular
adenomas less than 1 cm in size.
NEW FINDINGS
Patient factors such as race, family history and index
exam findings such as number or size of polyps were
associated with endoscopists recommending 3 versus
5-year intervals. However, when the follow up
colonoscopy exams were completed, neoplastic findings
were similar.
LIMITATIONS
The analysis did not examine 5 versus 10-year intervals as
outlined in the current guidelines.
IMPACT
These data support current guideline recommendations
for surveillance intervals of at least 5 years for
individuals with low risk adenoma.
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ATt is well recognized that individuals with 1 or 2 smallItubular adenomas are at low risk for subsequent
colorectal cancer (CRC) incidence and mortality1,2 or even
for advanced adenomas on follow-up exam.3–9 A pooled
report that combined data from 8 prospective studies
observed a lower risk for metachronous neoplasia in
subjects with low-risk adenomas (LRAs; 6.9%; 95% confi-
dence interval [CI], 6.2–7.6) as compared with those with
advanced neoplasia on index exam (15.5%; 95% CI,
14.5–16.6).6 A meta-analysis of 7 studies observed that the
incidence of metachronous advanced neoplasia in in-
dividuals with low-risk adenomas on an index exam was
small, ranging from 2.2 to 6.8%.10
However, despite this evidence, some endoscopists do
not adhere to current guidelines that recommend surveil-
lance interval of at least 5 years for individuals with low-
risk findings. Studies conducted in various settings have
observed that endoscopists often recommend intervals that
are shorter than 5 years for low-risk patients.11–14 Possible
explanations include a lack of knowledge about the guide-
lines, disagreement with the recommendations,15 or the
presence of other factors unique to the individual or exam,
such as inadequate bowel preparation.16–18
With both new technology and emphasis on lesion
detection, greater numbers of small tubular adenomas are
being detected during colonoscopy. Recent studies using
high-definition colonoscopes have demonstrated adenoma
detection rates of 40% to 60% in screenees.19–21 Thus, de-
cisions about the timing of follow-up surveillance colonos-
copy for individuals with these findings are made with
increasing frequency and can significantly affect the cost
effectiveness of CRC screening.
We used data from a recent adenoma prevention trial,
the Vitamin D/Calcium Polyp Prevention Study,22 to
examine the issue of follow-up of individuals with LRAs. Tobe enrolled, participants were required to have at least 1
adenoma removed shortly before study entry and a 3- or
5-year surveillance interval for follow-up colonoscopy.
Endoscopists, at the time of the qualifying colonoscopy,
determined the follow-up interval of either 3 or 5 years
based on their own clinical discretion and before decisions
about enrollment into the trial were made. We examined the
frequency of recommending shorter (3-year) vs longer
(5-year) intervals, as well as factors associated with rec-
ommending shorter intervals and the effect of that decision
on outcome at the time of follow-up colonoscopy.Methods
Data Source
The data used in our analysis were gathered during the
Vitamin D/Calcium Polyp Prevention Study, a double-blind,
placebo-controlled trial of 1000 IU daily vitamin D with or
without 1200 mg daily calcium supplementation for the pre-
vention of large bowel adenomas. The methods and results of
the main trial are published elsewhere and demonstrate that
the study agents did not confer a decreased recurrence of ad-
enomas.22 Briefly, adults age 45 to 75 years were enrolled from
11 study centers in North America from July 2004–July 2008.
Eligible subjects were required to have at least 1 histologically
confirmed adenoma, 2 mm or greater in diameter as estimated
by the endoscopist, removed during the 4 months prior to
study entry. In addition, eligible participants were also required
to have had a complete large bowel examination deemed free of
any remaining polyps by the endoscopist completing the exam.
In all cases, the qualifying colonoscopy (ie, detecting at least 1
adenoma 2 mm) and the clearing colonoscopy (ie, deeming
the colon free of remaining polyps) were the same examination
and will be simply referred to as the index exam below. Trial
eligibility also required that prior to enrollment subjects
receive either a 3- or 5-year recommended interval for sur-
veillance colonoscopy, as determined by the endoscopist at the
index exam. Participants were randomized in a modified 2 x 2
factorial design stratified by study center, sex and surveillance
interval, to 4 of 4 study arms: daily 1000 IU vitamin D3, 1200
mg calcium as carbonate, both, or placebo (4-group randomi-
zation). Women who declined to forego calcium supplementa-
tion were randomized to calcium alone or with vitamin D
(2-group randomization). In this analysis, we included subjects
who had only 1 or 2 tubular adenomas <1 cm in estimated
diameter (N ¼ 1560).
Exposure Data
Our first aim was to identify factors associated with shorter
3-year surveillance interval recommendations at the time of
study entry among subjects with only 1 or 2 small tubular
adenomas. Information on participants was obtained at
enrollment by a trained study coordinator using standardized
questionnaires and interview scripts, and included de-
mographics, family history of CRC, diet, medical history, and
lifestyle information such as smoking and alcohol use. Family
history of CRC (self-reported) was defined as having a first-
degree relative of any age diagnosed with CRC. Clinical data
including the indication for index examination were abstracted
from the colonoscopy and pathology reports and included
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colonoscopy, and pathology findings (see outcome data). Index
adenomas were stratified into 2 size categories (2–5 mm and
6-9 mm). While we did have information on the history of
having a prior exam, we did not have detailed information
regarding the findings in these exams. If the index colonoscopy
was the first exam for an asymptomatic participant, it was
considered a screening colonoscopy. Any exam performed in an
asymptomatic participant with a previous colonoscopy was
labeled as a follow-up exam. Finally, any exam that was per-
formed for symptoms was considered diagnostic. We also
included information gathered from publicly available Web
sites regarding participating endoscopists’ characteristics (age
at Index exam, sex, and specialty).CLOutcome Data
All tissue removed during follow-up colonoscopies was sent
for central study review by a single gastrointestinal trained
study pathologist. While the majority (90%; data not shown) of
the post-randomization colonoscopy exams were performed for
routine surveillance, some subjects had interim follow-up
exams performed for clinical indications. Our primary
outcome of interest was the detection of advanced neoplasia at
follow-up colonoscopy, including interim examinations. We also
conducted analyses of any detected adenoma and clinically
significant serrated polyps. An advanced adenoma was defined
as any adenoma that was 1 cm in diameter, as estimated by
the endoscopist, or having advanced pathology defined as
villous or tubulovillous histology, high-grade dysplasia, or
invasive cancer. A clinically significant serrated polyp included
sessile serrated adenomas, traditional serrated adenomas, and
hyperplastic or other serrated polyps that were 1 cm or
occurred in the proximal colon (the cecum, ascending colon,
hepatic flexure, or the transverse colon).Analytic Plan
For our analysis, we included subjects with only 1 or 2
small tubular adenomas on the index exam. Participant, exam,
and endoscopist-related characteristics were compared for
those who were recommended a 3- vs a 5-year follow-up in-
terval. A t-test was used to compare continuous variables and a
c2 test was used to compare categorical variables. A general-
ized linear model using a natural-logarithm link function and
Poisson-distributed errors adjusted for over/under dispersion
was used to estimate risk ratios of a 3-year vs a 5-year exam-
ination for each predictor separately. Variables with univariate
P values < .05 were then put in a multivariate model. Variables
with P > .05 were then removed successively until all variables
remaining were statistically significant.
One potentially important factor that could influence
follow-up decisions, but could not be adjusted for, was his-
tory of advanced neoplasia prior to the index colonoscopy for
the study. To address this issue, we performed a restricted
analysis including only participants with no prior colonos-
copy to determine if risk factors for early recall in this
restricted sample were similar to those identified in the
entire sample.
To assess whether there were differences in findings on the
follow-up exam according to the recommended surveillance
interval, we determined the absolute risk and risk ratios foreach of the following outcomes: at least 1 adenoma, at least 1
advanced adenoma, and at least 1 clinically significant serrated
polyp on follow-up exam. For the risk ratios, we used 2
modeling strategies. First, for each outcome, comparing the
recommended 3- to 5-year intervals, we computed risk ratios
and 95% confidence limits as above and adjusted for factors
related to trial participation including age, sex, clinical center,
randomization groups (2- or 4-group) and study treatments
(vitamin D vs no vitamin D and calcium vs no calcium). Second,
we performed more fully adjusted models accounting for clin-
ical factors that were associated with earlier recommended
follow-up and outcome. These included race (white, African
American, Asian/Pacific Islander, other), smoking status (never,
former, and current), body mass index (BMI; continuous),
family history of CRC (yes vs no), exam indication (as above),
number of adenomas at index exam, presence of clinically sig-
nificant serrated polyp on index exam, bowel preparation
(excellent, good, adequate, fair, poor, and not stated in report)
and endoscopist characteristics (age, gender, and specialty).
Most participants completed their follow-up colonoscopy
within a short window around the recommended follow-up
date. However, we also performed a secondary analysis
based on the actual surveillance intervals, irrespective of the
recommended dates.Results
Of the 2259 randomized subjects, there were 1560
subjects with 1 to 2 small (< 1 cm) adenomas on index
exam. In this sample, 594 (38%) had a recommendation for
a 3-year follow-up surveillance interval (Figure 1). We
observed that across the 11 recruitment centers there was a
broad range with regard to the proportion of participants
receiving 3-year surveillance recommendations (14%–77%;
see Figure 2). Comparisons of subject, index exam, and
endoscopist characteristics between individuals receiving 3-
vs 5-year follow-up recommendations are shown in Table 1.
There were no statistically significant differences between
these 2 groups with regard to subject age, sex, Hispanic
ethnicity, smoking history, BMI, or endoscopist gender. In
comparison with subjects with a 5-year recommendation,
those with a 3-year recommendation were more likely to be
African American (10.9% vs 6.7%; P < .001) Asian/Pacific
Islander (4.0% vs 1.6%; P < .0001), and have a family
history of CRC (21.0% vs 15.6%; P ¼ .01). Additionally,
across 3 BMI categories (<25, 25–29.9, and >30) there was
a non-significant trend for obese subjects to receive shorter
intervals than non-obese participants (P ¼ .09).
Subjects for whom the indication for the index exam was
determined to be follow-up were more likely to be given a 3-
year rather than a 5-year recommendation (50.3% vs 42.5%;
P¼ .01). Subjects with a 3-year recommendation were much
less likely to have excellent bowel preparation on index
(23.2%vs 42.1%; P< .0001). In about 20%of cases, no bowel
prep qualitywas reported for the exam. One center accounted
for over one third of all exams with missing bowel prepara-
tion (83/220). Endoscopists recommending shorter intervals
were on average 1.4 years younger than those recommending
5-year intervals and came from specialties other than
gastroenterology (10.5% vs 5.9%).
Figure 1. Derivation of the
low risk adenoma cohort
from the parent Vitamin
D/Calcium Polyp Preven-
tion Trial.
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exam that predicted a shorter 3-year interval recommenda-
tion. Those with a 3-year interval recommendation were
more likely to have 2 adenomas (27.4% vs 15.6%), at least 1
serrated polyp (30.3% vs 19.4%), and at least 1 clinically
significant serrated polyp (9.2% vs 6.0%) than were those
with 5-year interval recommendations (Table 1). Absolute
size of the adenomas at index exam was also important in
predicting the timing of follow-up. Subjects with at least 1
adenoma that was 6–9mm in size weremore likely to receive
a 3-year recommendation than those with only adenomas
that were 2–5 mm (41.7% vs 35.0% respectively; P ¼ .01).Figure 2. Variation of
3-year recommendation
for subjects with LRAs on
index exam by center.There was no association between the location of adenoma
and recommended follow-up interval (data not shown).
In the multivariate model, we identified factors that
were statistically significantly independently associated
with shorter interval recommendations (Table 2): African
American race, Asian/Pacific Islanders, persons with a
family history of CRC, those who had 2 adenomas (rather
than 1) on their index exam, and those who had any
serrated polyps. In addition, participants who had less than
an excellent quality of preparation were all more likely to
have a 3-year interval recommendation than those with an
excellent quality of bowel preparation.
Table 1.Selected Study Participant, Colonoscopy Exam, and Endoscopist Characteristics by Recommended 3- vs 5-Year
Follow-up Colonoscopies for Previous LRAs
Category Factor 3-year (%) (N¼594) 5-year (%) (N¼966) P value
Subject Age, mean ± SD 58.0 ± 6.9 57.7 ± 6.7 .37
Sex .77
Male 361 (60.8) 580 (60.0)
Female 233 (39.2) 386 (40.0)
Race
White 482 (81.1) 821 (85.0) <.0001
African American 65 (10.9) 65 (6.7)
Asian/Pacific Islander 24 (4.0) 15 (1.6)
Other/multiple/unknown 23 (3.9) 65 (6.7)
Hispanic ethnicitya
No 554 (93.4) 898 (93.0) .73
Yes 39 (6.6) 68 (7.0)
Smoking status .15
Never 303 (51.0) 538 (55.7)
Former 235 (39.6) 355 (36.8)
Current 56 (9.4) 73 (7.6)
BMIa .09
<25 140 (23.6) 224 (23.3)
25-29.9 222 (37.4) 410 (42.6)
 30 232 (39.1) 329 (34.2)
Family history of CRCa
No 434 (79.1) 763 (84.4) .01
Yes 115 (21.0) 142 (15.6)
Exam Indicationa .01
Screening 208 (35.1) 387 (40.2)
Follow-up exam 298 (50.3) 409 (42.5)
Diagnostic 87 (14.7) 166 (17.3)
Quality of preparation Pre-preparationa <.0001
Excellent 138 (23.2) 407 (42.1)
Good 232 (39.1) 348 (36.0)
Adequate 47 (7.9) 62 (6.4)
Fair 50 (8.4) 44 (4.6)
Poor 2 (0.3) 0 (0.0)
Not stated in report 125 (21.0) 105 (10.9)
Endoscopista Age (mean years ± SD) 47.3 ± 8.1 48.7 ± 9.6 .003
Gender
Male 519 (87.5) 820 (84.9) .15
Female 74 (12.5) 146 (15.1)
Specialty <.0001
Gastroenterology 531 (89.5) 909 (94.1)
Internal medicine 29 (4.9) 43 (4.5)
General surgery 26 (4.4) 12 (1.2)
Other 7 (1.2) 2 (0.2)
Index findings No. of adenomas <.0001
1 431 (72.6) 815 (84.4)
2 163 (27.4) 151 (15.6)
No. of serrated polyps <.0001
0 414 (69.7) 779 (80.6)
1–2 150 (25.3) 174 (18.0)
3þ 30 (5.1) 13 (1.4)
Clinically significant serrated polypa
No 531 (90.8) 897 (94.0) .02
Yes 54 (9.2) 57 (6.0)
BMI, body mass index; CRC, colorectal cancer; SD, standard deviation.
aMissing data not included above: Hispanic (n¼1), BMI (n¼3), Family history of CRC (n¼106), Exam indication (n¼5),
Endoscopist information (n¼1), clinically significant serrated polyp (n¼21).
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tory, we performed a restricted analysis examining factors
associated with 3- vs 5-year interval recommendations insubjects whose qualifying exam was their first lifetime
examination (n ¼ 606). We observed a similar proportion
of exams with earlier recall (215/606; 35.5%) as in the
Table 2.Relative Risk of Recommended 3 vs. 5-Year Follow-up in Subjects With index LRAs
Category Factor
Unadjusted univariate
RR (95% CI)
Multivariatea RR (95%CI)
(N¼1453) P value
Subject Age (per 10 y) 1.04 (0.95–1.15)
Sex
Male reference
Female 0.98 (0.86–1.12)
Race
White reference reference .004
Black 1.35 (1.10–1.66) 1.41 (1.14–1.75)
Asian/Pacific Islander 1.66 (1.20–2.30) 1.72 (1.22–2.43)
Other/multiple/unknown 0.71 (0.51–0.98) 0.73 (0.52–1.03)
Hispanic (% yes)
No reference
Yes 0.96 (0.74–1.23)
Smoking status
Never reference
Former 1.11 (0.97–1.26)
Current 1.20 (0.96–1.51)
BMI
<25 reference
25–29.9 0.91 (0.77–1.08)
 30 1.08 (0.91–1.27)
Family history of CRC
No reference reference .01
Yes 1.23 (1.05–1.45) 1.26 (1.07–1.48)
Exam Indication
Screening reference
Follow-up exam 1.21 (1.05–1.39)
Diagnostic 0.98 (0.81–1.20)
Quality of preparationa <.0001
Excellent reference reference
Good 1.58 (1.34–1.87) 1.50 (1.26–1.78)
Adequate 1.70 (1.31–2.21) 1.60 (1.23–2.10)
Fair/poor 2.14 (1.66–2.75) 2.16 (1.66–2.83)
Not stated in report 2.15 (1.77–2.60) 2.12 (1.74–2.60)
Endoscopist Age (per 10 years) 0.90 (0.84–0.97)
Gender
Male reference
Female 0.87 (0.72–1.05)
Specialty .001
Gastroenterology reference reference
Internal medicine/General surgery/Other 1.41 (1.15–1.74) 1.45 (1.16–1.79)
Index findings No. of adenomas <.0001
1 reference reference
2 1.50 (1.30–1.73) 1.47 (1.27–1.71)
No. of serrated polyp .0003
0 reference reference
1–2 1.33 (1.15–1.55) 1.29 (1.10–1.50)
3þ 2.01 (1.50–2.69) 2.16 (1.59–2.93)
Clinically significant serrated polypb
No reference
Yes 1.31 (1.05–1.63)
BMI, body mass index; CI, confidence interval; CRC, colorectal cancer; RR, relative risk.
aMultivariate model after removing variables stepwise with P < .05.
bA clinically significant serrated polyp is defined as a sessile serrated adenoma, a traditional serrated adenoma, a proximal
serrated polyp, or a serrated polyp 1 cm.
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similar to those in the overall sample with regard to
factors that were significantly associated with 3-year in-
terval recommendations (see Supplementary Table 1).
Analyses examining the risk for metachronous advancedneoplasia demonstrated no significant association with
factors that were associated with earlier surveillance in-
terval selection or other known colorectal neoplasia risk
factors such as smoking or obesity (Supplementary
Table 2).
Figure 3.Outcomes at
follow-up colonoscopy for
participants with surveil-
lance exams reommended
at 3 vs 5 years.
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Supplementary Table 3. The mean time to follow-up exam in
the 3-year group was 39.6 months (standard deviation þ
7.2 months) and 61.0 (± 8.5 months) in the 5-year group.
While 81.4% of subjects in the 3-year group had their sur-
veillance exam within 6 months of the recommended in-
terval, 75% of those in the 5-year group had a repeat in that
time frame. Subjects in the 5-year group were more likely to
have an exam sooner than 6 months prior to the expected
date (9.9% vs 1.1%) while those in the 3-year group were
more likely to have an exam 6 months or longer after the
expected date (19.9% vs 15.1%).
There were no significant differences between the 3- vs
5-year groups for risk of 1 adenomas (38.8% vs 41.7%;
P ¼.27, respectively), advanced adenomas (7.7% vs 8.2%;
P ¼ .73), or a clinically significant serrated polyp (10.0% vs
10.3%; P ¼ .82) at follow-up colonoscopy (Figure 3). A large
proportion of these metachronous clinically significant
serrated polyps were proximal hyperplasic polyps  5 mm
(92/213; 43.2%). There were 4 CRCs detected (3 in the
3-year group and 1 in the 5-year group (Supplementary
Table 4).Given the importance of prep quality to neoplasia
detection, we performed an analysis examining recurrence
in the 3- and 5-year groups in a sample restricted to those
with good or excellent preparation, removing participants
with no reported bowel preparation quality as well as
those with poor or fair preparation. We observed that risk
for advanced adenomas on surveillance exam was the same
(8.4%) for the 3- and 5-year-groups (data not shown).
In our primary multivariate models, the recurrence risk
ratio for a 3-year vs a 5-year interval was 0.86 (95%
CI¼ 0.59–1.27) for advanced adenoma, 0.94 (95% CI¼ 0.82–
1.08) for any adenoma, and 0.97 (95% CI ¼ 0.68–1.38) for
clinically significant serrated polyps (Figure 3). In a secondary
model adjusting for clinical factors associated with a short
interval recommendation, we also observed no significant
differences between the 3- and 5-year groupswith regard to 1
or more adenomas, advanced adenomas, or clinically signifi-
cant serrated polyp on follow-up exam (Supplementary
Table 5).
We repeated these analyses using the actual timing of the
surveillance exams rather than the recommended interval.
There were no significant differences between the absolute
1940 Anderson et al Gastroenterology Vol. 152, No. 8
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ATrisks for participants with a 30- to 42-month follow-up vs
those recalled at 54–66-months group for risk of 1 ade-
nomas (37.0% vs 40.7%; P ¼ .21, respectively), advanced
adenomas (8.0% vs 6.8%; P ¼ .42), or a clinically significant
serrated polyp (11.1% vs 11.5%; P ¼ .83). Adjusted model
results are shown in Supplementary Table 6.Discussion
Using data from a large chemoprevention trial, we
observed 2 important findings regarding the surveillance of
subjects with LRAs. In our sample, a significant proportion
of subjects (38.1%) with 1 to 2 small adenomas on index
exam were recommended to have a follow-up exam at 3
years. This 3-year interval was substantially shorter than
the 5-year surveillance interval recommended by US Multi-
Society Task Force (USMSTF) guidelines prevailing at the
time of the study.23,24 Despite the difference in intervals,
there were no significant differences in pathology between
the 3- and 5-year groups on follow-up colonoscopy.
The 5-year post polypectomy colonoscopy interval
recommendation by the USMSTF on CRC for individuals
with LRAs was first published in 2003,23 a year before the
start of the current study’s enrollment period, July 2004.
The change in the recommended interval, an increase from 3
to 5 years, was based on published reports that found a
lower risk for advanced lesions on follow-up examinations
among individuals who had LRAs on a previous colonos-
copy.25 The recommendation of 5 years was extended to 5
to 10 years in a subsequent version of the guidelines that
was published in 2006, during the enrollment period.24
Thus, despite guideline recommendations as well as pub-
lished data, a shorter recommendation of 3 years was made
for a large proportion of subjects with LRAs.
Our findings demonstrate a large variation in recom-
mendations for the timing of post polypectomy colonoscopy
across study centers: While 77% of exams had a 3-year
interval at 1 center, another reported only 14%. A large
percentage of colonoscopies in our study were performed at
intervals shorter than those endorsed in published guide-
lines, supporting results of previously published stud-
ies7,8,11–15,21,26–30 (see Supplementary Table 7). While most
studies suggest that endoscopists are recommending
shorter intervals, a recent analysis of Veterans Affairs
Medical Center patients who had a colonoscopy in 2008
observed non-compliance for individuals with high-risk
adenomas on index but not those with LRAs.31
The reasons for a recommendation disparate from the
USMSTF are likely multifactorial. A survey of gastroenter-
ologists conducted just after the current trial’s enrollment
period observed that although 63.6% of gastrointestinal
physicians were cognizant of the correct surveillance of 5
years for 2 small adenomas, a large proportion (28.8%) of
the physicians disagreed with this interval.15 While it may
not be possible to determine the exact motivation for the
endoscopists in our population to recommend a shorter
interval, we did identify some factors that were associated
with a 3-year interval recommendation. Subjects with a
family history of CRC were more likely to have a 3-yearrecommendation than those with no family history.
Currently, the recommendation for colonoscopic surveil-
lance intervals of patients with a family history of CRC but
no adenomas is either 5 or 10 years, depending on the age
of the CRC diagnosis in the relative; there are no specific
surveillance recommendations for individuals who have a
family history of CRC as well as an adenoma on colonoscopy.
Other factors that were associated with a 3-year interval
recommendation in our study population included having 2
adenomas (vs 1) or at least 1 adenoma 6–9 mm in size (vs
those with only adenomas 2–5 mm in size) or multiple
serrated polyps on index exam.We also observed that African
American adults andAsian/Pacific Islandersweremore likely
to receive 3-year intervals than white adults. This finding
supports an analysis of Medicare data that also observed that
African American adults were more likely than white in-
dividuals to have an early repeat colonoscopy after a normal
exam.32 The American College of Gastroenterology CRC
Screening Guidelines has also recommended that African
American adults be screened at 45 years because of their
increased risk of CRC.33 Thus, there may be a heightened
concern among endoscopists regarding neoplasia risk in Af-
rican American adults, though their risk for metachronous
neoplasia after polypectomy may be similar to that for white
adults.34 Thus, given the factors we identified in our analysis,
it is likely that endoscopists may have provided shorter in-
tervals to individuals whom they believed to be at higher risk
for advanced neoplasia on the basis of race, family history of
CRC, and findings at colonoscopy.
However, these factors were not associated with the risk
of metachronous neoplasia, and despite the differences in
characteristics at index exam between the 3-year and 5-year
groups, there was no statistically significant difference in
risk for being diagnosed with an advanced adenoma during
follow-up (7.7% vs 8.2%, respectively). Of note, the preva-
lence of clinically significant serrated polyps was high at
follow-up, approximately 10% for both groups. Over the
time frame of the trial, serrated neoplasia was increasingly
recognized and identified by endoscopists. We suspect that
the high rate of follow-up serrated neoplasia, a large pro-
portion of which were diminutive hyperplastic polyps
(92/213; 43.2%), reflects missed lesions at the index exam.
In addition to patient-specific factors, we also identified
some procedure-related predictors. In our study, we
observed that individuals whose bowel preparation on index
examwas not rated as excellent were more likely to receive a
3-year recommendation. Inadequate bowel preparation has
previously been found to be a potential factor in endoscopists
recommending shorter intervals.17,18,31,35 Our inclusion
criteria, which required a complete inspection of the large
bowel, minimized the number of subjects with a poor or fair
preparation quality. Thus, our ability to examine poor or fair
bowel preparation as a predictor of early surveillance
recommendation may have been limited by low power
because of the small numbers of exams with poor (n ¼ 2) or
fair (n¼ 94) preparation. In our study, we also observed that
non-gastroenterologists were more likely to recommend 3-
year intervals to individuals with LRAs than gastroenterolo-
gists. This finding is consistent with previous research
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recommend shorter call back intervals than those outlined in
guidelines.28 A recent study of 25 Veterans Affairs Medical
Center facilities found that general surgeonsweremore likely
to overuse colonoscopy than gastroenterologists.36
A key finding of our paper is that neoplasia detection at
follow-up was similar between the 3- and 5-year groups. In
the National Polyp Study,37 similar detection of neoplasia at
1 and 3 years provided strong evidence to lengthen the
interval to first surveillance and we believe our results
should be interpreted similarly. However, because our study
is not a clinical trial directly comparing the 2 intervals, we
cannot exclude confounding from our analyses examining
adenoma and advanced adenoma detection at follow-up. To
the extent that the 3-year group is enriched with those at
higher risk, comparison of follow-up findings would be
potentially confounded. However, we observed no associa-
tion between index exam factors that were associated with
earlier recommendation and the risk of detecting meta-
chronous advanced neoplasia on surveillance exams (See
Supplementary Table 2). To further address the concern
that endoscopists had identified significant factors, we
examined our outcomes after adjusting for the co-variates in
Table 1 and observed no significant differences between
these results and those from our analyses that adjusted only
for trial specific factors (see Supplementary Table 5).
Finally, with regards to the impact of surveillance in-
terval timing, we believe that 2 years would have made little
difference with regard to adenoma development. An anal-
ysis of the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial observed that all participants with LRAs on
index exam had a similar risk for advanced neoplasia
despite a follow-up period that ranged from 6 months to 10
years.38 In addition, the National Polyp Study observed no
difference in adenomas detected on surveillance exams
performed at 1 vs 3 years post index colonoscopy.37
One of the strengths of our study is that our findings
represent “real life” experience because the practicing
endoscopists selected the interval for the subjects with LRAs
before study enrollment, thus avoiding biases associatedwith
trial enrollment prior to interval selection. This allowed us to
identify important possible predictors for shorter surveil-
lance recommendations. In addition, this analysis presents
follow-up data for subjects who had been recommended a
3- vs 5-year surveillance interval, allowing a direct compar-
ison of these 2 intervals. Our study had a large sample size,
and because the participants were enrolled in a chemopre-
vention trial, we had high quality, prospectively collected
data for our exposures and outcomes of interest, and nearly
complete follow-up of the study participants. There were 11
participating centers across the US, representing a broad
representation of gastrointestinal practices, increasing the
generalizability of our results.
A potential limitation of our study is that our main ana-
lyses were based on recommendation intervals and this may
not be the same as the actual time period in which the follow-
up examwas performed. However, nearly 80%of the subjects
in each group (81.4% for 3-year and 75% for the 5-year
group) received their follow-up exam within 6 months ofthe respective recommended interval. We examined the
impact of the actual timing of the surveillance exam on the
outcomes and observed no significant differences between
these results and those obtained when examining the data by
recommendation intervals. In addition, we did not have data
regarding personal history of adenomas before the index or
qualifying exam.39 Prior work from our group demonstrated
that those with a history of advanced adenomas were at
increased risk for advanced neoplastic findings both at the
next examand the subsequent (ie, third) colonoscopy exam.39
Although individuals with a previous history of CRC were
excluded in our analysis, there may have been some subjects
with a history of advanced adenomas, which may have
influenced the endoscopist’s decision making regarding sur-
veillance intervals. To address this limitation, we performed a
restricted analysis in subjects whose qualifying exam was
their first lifetime exam and found generally similar findings.
Another limitation is thatwe had a relatively large percentage
of exams with no reported quality of bowel preparation.
However, we performed a sensitivity analysis by removing
these exams aswell as thosewith poor or fair preparation and
observed that risk for advanced adenomas on surveillance
exam was the same for the 3- and 5-year groups. Finally, our
analysis does not examine 5- vs 10-year intervals as outlined
in the current guidelines. However, we suspect that factors
predicting short follow-up would likely be similar. To the
extent that individuals just a few years agowere still selecting
3-year intervals, our data provides support for a 5-year
minimum.
In summary, our findings suggest that a large percentage
of endoscopists recommend follow-up colonoscopy in-
tervals for LRAs that are shorter than those recommended
by guidelines. In addition, there were statistically significant
differences between study participants recommended 3- vs
5-year follow-up colonoscopies with regard to family his-
tory and number of adenomas and serrated polyps. Despite
these differences, there was no substantial difference in
outcome findings on follow-up exam. A survey conducted by
the National Cancer Institute found that with regard to
surveillance recommendations, physicians were more likely
to be influenced by published evidence than by guidelines.28
Thus, our findings of similar rates of advanced adenomas
detected after 3- or 5-year intervals in persons who had
LRAs on their previous exam may help dissuade endo-
scopists from recommending shorter surveillance intervals
for their patients.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2017.02.010.References
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Supplementary Table 1.Restricted to Subjects for Whom Qualifying was the First Lifetime Exam
Category Factor 3-year (N ¼ 215) (%) 5-year (N ¼ 391) (%) P value
Subject Age mean ± SD 58.0 ± 5.6 54.9 ± 5.7 .82
Sex .40
Male 122 (56.7) 208 (53.2)
Female 93 (43.3) 183 (46.8)
Race
White 176 (81.9) 330 (84.4) .21
Black 18 (8.4) 25 (6.4)
Asian/Pacific Islander 9 (4.2) 7 (1.8)
Other/multiple/unknown 12 (5.6) 29 (7.4)
Hispanic ethnicitya
No 196 (91.6) 360 (92.1) .84
Yes 18 (8.4) 31 (7.9)
Smoking status .15
Never 118 (54.9) 234 (59.9)
Former 72 (33.5) 129 (33.0)
Current 25 (11.6) 28 (7.2)
BMIa .05
<25 55 (25.6) 99 (25.5)
25-29.9 72 (33.5) 165 (42.4)
 30 88 (40.9) 125 (32.1)
Family history of CRC
No 170 (84.2) 326 (88.4) .16
Yes 32 (15.8) 43 (11.7)
Exam Indicationa .99
Screening 173 (80.5) 314 (80.5)
Follow up exam 0 0
Diagnostic 42 (19.5) 76 (19.5)
Quality of Pre-preparationa <.0001
Excellent 51 (23.7) 170 (43.5)
Good 86 (40.0) 130 (33.3)
Adequate 17 (7.9) 31 (7.9)
Fair 18 (8.4) 18 (4.6)
Poor 1 (0.5) 0 (0.0)
Not stated in report 42 (19.5) 42(10.7)
Endoscopista Age (mean y ± SD) 47.1 ± 7.9 48.2 ± 9.7 .001
Gender
Male 184 (86.0) 333 (85.2) .79
Female 30 (14.0) 58 (14.8)
Specialty .03
Gastroenterology 187 (87.4) 365 (93.4)
Internal medicine 14 (6.5) 19 (4.9)
General surgery 10 (4.7) 5 (1.3)
Other 3 (1.4) 2 (0.5)
Index findings No. of adenomas <.0001
1 156 (72.6) 345 (88.2)
2 59 (27.4) 46 (11.8)
No. of serrated polyps .01
0 155 (72.1) 312 (79.8)
1–2 51 (23.7) 75 (19.2)
3þ 9 (4.2) 4 (1.0)
Clinically significant serrated polypb
No 196 (92.0) 366 (94.1) .33
Yes 17 (8.0) 23 (5.9)
aMissing data not included above: Hispanic (n¼1), BMI (n¼3), Family history of CRC (n¼106), exam indication (n¼5), endo-
scopist information (n¼1), clinically significant serrated polyp (n¼21).
bA clinically significant serrated polyp is defined as a sessile serrated adenoma, a traditional serrated adenoma, a proximal
serrated polyp, or a serrated polyp 1 cm.
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Supplementary Table 2.Risk of Advanced Adenoma for Risk Factors in Table 1 of Paper
N events/N (%) Adjusteda RR (95% CI)
Race White 97/1210 (8.0) reference
Other 15/159 (9.4) 0.98 (0.55–1.74)
Smoking status Never 57/783 (7.3) reference
Former/current 58/648 (9.0) 1.19 (0.83–1.71)
BMI <30 71/921 (7.7) reference
30 44/509 (8.6) 1.09 (0.76–1.57)
Family history of CRC No 94/1100 (8.6) reference
Yes 18/241 (7.5) 0.88 (0.54–1.43)
Indication Screening/diagnostic 55/658 (8.4) Reference
Follow-up exam 60/768 (7.8) 1.00 (0.68–1.45)
Quality of preparation Excellent/good 89/1039 (8.6) Reference
Adequate/fair/poor 14/187 (7.5) 0.66 (0.37–1.19)
Not stated in report 12/205 (5.9) 0.66 (0.34–1.28)
Endoscopist age 45 47/561 (8.4) Reference
>45 68/869 (7.8) 0.93 (0.64–1.34)
Endoscopist gender Male 100/1228 (8.1) Reference
Female 15/202 (7.4) 0.86 (0.50–1.47)
Specialty Gastroenterology 104/1325 (7.9) Reference
Other 11/105 (10.5) 1.41 (0.69–2.89)
No. of adenomas 1 90/1141 (7.9) Reference
2 25/290 (8.6) 1.08 (0.70–1.67)
No. of serrated polyps 0 82/1102 (7.4) reference
1þ 33/329 (10.0) 1.43 (0.96–2.12)
aAdjusted for age, sex, study center, randomization group (2-group or group), Vitamin D treatment and Calcium treatment
(women in the 2-group randomization who were taking non-randomized calcium are grouped with the calcium treated
subjects).
Supplementary Table 3.Details of Follow-up Colonoscopies According to Recommended 3- or 5-year Follow-up
3-year recommendation
N (%)
5-year recommendation
N (%) P value
Timing of study follow-up exam <.0001
More than 6 mos before due date 6/559 (1.1) 87/880 (9.9)
Within 6 mos before or after due date 455/559 (81.4) 660/880 (75.0)
More than 6 mos after due date 98/559 (19.9) 133/880 (15.1)
Time from index to follow-up exam (mos)
Mean (SD) 39.6 ± 7.2 61.0 ± 8.5
Range 15.7–77.6 19.1–101.9
Contributed follow-up outcome dataa .03
No 35/594 (5.9) 86/966 (8.9)
Yes 559/594 (94.1) 880/966 (91.1)
aThis includes subjects who had any exam after randomization during the treatment phase of the parent study and there was
sufficient pathology to ascertain at least 1 of our outcomes of interest.
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Supplementary Table 4.Selected Study Participant,
Colonoscopy Exam, and
Endoscopist Characteristics for the
4 CRCs at Follow-up
Category Factor n
Subject Age ¼ 51, 53, 58, 70
Sex
Male 1
Female 3
Race
White 4
Hispanic ethnicity
No 4
Smoking status
Never 2
Current 2
BMI
<25 1
25–29.9 2
 30 1
Family history of CRC
No 4
Exam Indication
Screening 1
Follow-up exam 3
Quality of pre-preparation
Excellent 2
Good 1
Fair 1
Endoscopist Age ¼ 33, 39, 45, 58
Gender
Male 3
Female 1
Specialty
Gastroenterology 4
Index findings No. of adenomas
1 3
2 1
No. of serrated polyps
0 1
1–2 3
Clinically significant serrated polyp
No 4
Supplementary Table 5.Outcomes at Follow-up With
Additional Covariates
Outcome
Adjusted RR
(95% CI)a
P
value
1 or more adenomas
3-year recommended follow-up 0.95 (0.82–1.10) .49
5-year recommended follow-up reference
Advanced adenoma
3-year recommended follow-up 0.89 (0.59–1.35) .58
5-year recommended follow-up reference
Clinically significant serrated polyp
3-year recommended follow-up 0.93 (0.64–1.33) .68
5-year recommended follow-up reference
aAdjusted for age, sex, study center, randomization group
(2-group or 4-group), Vitamin D treatment and Calcium
treatment (women in the 2-group randomization who were
taking non-randomized calcium are grouped with the calcium
treated subjects), race (white, black, other), smoking status
(ever, never), BMI (continuous), family history of CRC
(including those with missing history as a separate category
(yes, no, missing), indication (screening, surveillance, symp-
toms), number of adenomas at baseline (1, 2), clinically sig-
nificant serrated polyp at baseline (no, yes), bowel prep
(excellent, good, satisfactory/fair/poor, missing), endoscopist
age (continuous), endoscopist gender, endoscopist specialty
(gastro/other).
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Supplementary Table 6.Outcomes at Follow-up Colonoscopy for Participants With Surveillance Exams at 3 vs 5 Years
(Actual Time of Exam, not Recommended Interval)
Outcome N events/N (%) c2 P value Adjusted RR (95% CI)a P value
1 or more adenomas .21
Follow-up at 30–42 mos 183/495 (37.0) 0.90 (0.77–1.06) .21
Follow-up at 54–66 mos 261/642 (40.7) reference
Advanced adenoma .42
Follow-up at 30–42 mos 40/500 (8.0) 1.07 (0.69–1.65) .78
Follow-up at 54–66 mos 44/652 (6.8) reference
Clinically significant serrated polypb .83
Follow-up at 30–42 mos 54/488 (11.1) 0.95 (0.66–1.36) .79
Follow-up at 54–66 mos 72/627 (11.5) reference
Note there are 282 people not in this table who were in Figure 3 in the paper because some subjects had exams outside the
36 ± 6 and 60 ± 6 month windows.
aAdjusted for age, sex, study center, randomization group (2-group or 4-group), Vitamin D treatment and calcium treatment
(women in the 2-group randomization who were taking non-randomized calcium are grouped with the calcium treated
subjects).
bA clinically significant serrated polyp is defined as a sessile serrated adenoma, a traditional serrated adenoma, a proximal
serrated polyp, or a serrated polyp 1 cm.
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Supplementary Table 7.Literature Survey of Management of Small Adenomas by Physicians
Study Design Setting N Finding
Mysliwiec et al, 2004, US28 Survey from National Cancer
Institute
National representative study
of endoscopists
349 gastroenterologists/
316 general surgeons
More than 50% recommended 3 or fewer years
surveillance for a small adenoma
Boolchand et al, 2006, US30 Survey of primary care
physicians
Random sample of 500
College of Physicians & 500
American
Academy of Family Physicians
568/1000 physicians
responded
71% would survey a small tubular
adenoma in  3 years &
80% would survey 2 small tubular
adenomas  3 years
Krist et al, 2007, US11 Chart review Primary care practices in
Maryland/Virginia
3000 charts from 10 practices 68.1% recommended surveillance interval of
< 5 years for LRAs
Saini et al, 2009, US15 Survey at board review course Gastroenterologists at board
review course
for 2004 recertification
116/203 completed the survey 48.2% correctly knew 5-year interval for LRAs
28.8% disagreed with this recommendation
Laiyemo et al, 2009, US7 Prospective cohort analysis
of PLCO participants
PLCO subjects 1297 participants 30.3% of 431 subjects with LRAs had repeat
colonoscopy within 4 years and probability
of advanced adenoma was 5%
Schoen et al, 2010, US14 Retrospective survey of
PLCO participants
PLCO trial in 9 US communities 3627/3876 (93.6%) responded 46.7% of subjects with low-risk findings had
colonoscopy within 5 years of index
33.6% had surveillance colonoscopy within
4 years
Ransohoff et al, 2011, US13 Chart review Endoscopy practices in
North Carolina
322 physicians’ charts from
126 practices
35% of subjects with LRAs were asked to return
in 1–3 years
Radaelli et al, 2012, Italy8 Chart review Endoscopy units in Italy Charts from 902/7081
outpatients from 29
Italian endoscopy units
67.4% subjects with LRAs had surveillance
interval earlier than recommended
Kruse et al, 2015, US12 Chart review of patient
50-65 years
Primary care patients at Harvard
Vanguard Medical Associates
(multispecialty group)
1740 patients’ charts Endoscopists recommended earlier surveillance
in 39% of 257 exams with LRAs
Sohn et al, 2014, Korea27 Survey Members at a 64th Annual
Congress of Korean
Surgical Society
38/41 responders More than 50% recommended a 3-year or less
interval for LRAs
Meneeset al, 2014, US29 Chart review Tertiary-care and VAMC
in Michigan
922 colonoscopies 13.8% of endoscopies have < 5 year
recommended surveillance interval
van Heijningen et al, 2015,
Netherlands26
Chart review of colonoscopies
performed 1998–2002
Endoscopy units in the
Netherlands
2997 patients’ exams < 25% of patients received proper surveillance
Higher rate advanced adenoma in delayed
follow-up
Johnson et al, 2015, US31 Retrospective review of EMR
and administrative data
Multicenter Veterans Affairs 25 VA centers; charts from 1455
patients (50–60 y old)
They did not report proportions of non
adherence but observed that the risk for non
adherence was higher for hyperplastic and
high-risk but not LRAs
Murphy et al, 2016, US36 Retrospective review of EMR
and administrative data
Multicenter Veterans Affairs 25 VA centers; charts from
1455 patients (age 50–60)
26% overuse for LRAs
Predictors of overuse; female sex of patient,
general surgeon endoscopist and non-
academic facility
EMR, electronic medical record; LRAs, low-risk adenomas; PLCO. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
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